NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) had its price objective upped by Scotiabank from $35.00 to $47.00 in a research note published on Wednesday morning,Benzinga reports. They currently have a sector outperform rating on the stock.
A number of other brokerages have also recently commented on NAMS. Piper Sandler reissued an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, NewAmsterdam Pharma currently has an average rating of “Buy” and an average target price of $36.20.
Check Out Our Latest Stock Analysis on NewAmsterdam Pharma
NewAmsterdam Pharma Price Performance
Insider Buying and Selling
In other news, CAO Louise Frederika Kooij sold 45,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total value of $707,400.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $25.08, for a total value of $834,486.84. Following the sale, the insider now directly owns 11,778,760 shares of the company’s stock, valued at $295,411,300.80. This represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 86,803 shares of company stock valued at $1,755,307 in the last ninety days. 19.50% of the stock is owned by company insiders.
Institutional Investors Weigh In On NewAmsterdam Pharma
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise bought a new stake in NewAmsterdam Pharma during the 2nd quarter valued at $38,000. Quarry LP increased its position in NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after purchasing an additional 6,247 shares during the period. Barclays PLC increased its holdings in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after buying an additional 7,199 shares during the period. Bellevue Group AG purchased a new position in shares of NewAmsterdam Pharma in the 3rd quarter valued at $128,000. Finally, XTX Topco Ltd purchased a new position in NewAmsterdam Pharma in the third quarter valued at about $187,000. Institutional investors own 89.89% of the company’s stock.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
See Also
- Five stocks we like better than NewAmsterdam Pharma
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- What Are Dividend Challengers?
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Top Biotech Stocks: Exploring Innovation Opportunities
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.